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OBJECTIVES: Prior to being considered for funding at a provincial level, all oncolog-
ics must first be appraised at a national level by the pan-Canadian Oncology Drug 
Review (pCODR), except in Quebec. This research aims to explore whether there 
are any differences between the speed of provincial oncologic access and whether 
this varies by provincial wealth and/or population. METHODS: All publically avail-
able provincial funding summaries were extracted from the pCODR website up 
to October 2014 from which the appraisal outcomes and dates were extracted. 
The population, GDP and GDP per capita of each province was extracted from the 
Government of Canada statistics website. Statistical comparisons were performed 
using one-way ANOVA and Student’s t-tests. RESULTS: The average delay between 
pCODR recommendations and provincial funding decisions was 8.9 months, which 
significantly varied by province (p< 0.0001), with the lowest being British Columbia 
(2.8 months) and the highest being Prince Edward Island (15.1 months). The 4 prov-
inces with populations lower than 1 million experience significantly greater delays 
to access versus the 5 provinces whose population exceeded 1 million (12.4 vs. 6.1 
months, p< 0.005). The 4 provinces whose GDP exceeds CAD75,000 million experi-
ence significantly faster time to access than the 5 provinces whose GDP is lower than 
this (5.1 vs. 12.0 months, p< 0.005). However, this relationship does not reach sig-
nificance when GDP is examined on a per capita basis (top 4 provinces: 7.2 months 
vs. 10.3 months for the bottom 5, p= 0.11). CONCLUSIONS: There are significant 
variations in time to access for oncology drugs between different provinces. This is 
significantly related to the province population and overall wealth but not wealth 
on a per person basis. Further research can define whether this reflects differences 
in provincial assessments or whether pharmaceutical companies are prioritising 
larger provinces where better market returns can potentially be realised.
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OBJECTIVES: The pan-Canadian Oncology Drug Review (pCODR) makes recommen-
dations at a national level for oncology drugs. Drugs can only move to provincial 
consideration if they receive a pCODR “recommendation” or “recommendation 
conditional on cost-effectiveness being improved to an acceptable level”. This 
research aims to explore if pCODR deeming an oncologic to have acceptable cost-
effectiveness can affect the speed of attaining provincial access. METHODS: All 
publically available pCODR appraisal reports and provincial funding summaries up 
to 31 September 2014 were identified from which the appraisal outcomes, incre-
mental cost-effectiveness ratios (ICERs) and dates were extracted. If more than 1 
ICER was stated, the mean value was used. Statistical comparisons were performed 
using Student’s t-tests. RESULTS: pCODR submissions encompassing 34 indica-
tions were extracted. ICERs were only stated in 13/34 of these submissions. 2/13 
were pCODR-recommended, 11/13 recommended conditional on cost-effectiveness 
being improved to an acceptable level, and 0/13 rejected. There was no significant 
difference between average delay in provincial access for the submissions that 
received a full recommendation versus those that received a conditional recom-
mendation (9.3 vs 9.3 months, p= 0.49). However, the 7 drugs with an ICER above 
CAD200,000 per Quality–Adjusted Life Year (QALY) experienced significantly longer 
delays to provincial access than the 6 drugs whose ICERs fell below this level (12.3 
vs. 8.4 months, p= 0.02). CONCLUSIONS: Oncology drugs that are deemed to have 
acceptable cost-effectiveness by pCODR did not seem to attain faster provincial 
access, although this analysis was limited by the small number of positive pCODR-
recommendations with publically available ICERs. Nevertheless, oncologics with 
higher ICERs experienced significantly greater delays to provincial access. This sug-
gests that by making greater efforts to demonstrate cost-effectiveness at the level 
of pCODR, faster provincial and patent access can be obtained.
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OBJECTIVES: The Food and Drug Administration (FDA) have approved 28 onco-
logics across 37 indications on the basis of a clinical trial package lacking com-
parative Phase III data (Macaulay, ISPOR Toronto 2014). Approval was typically 
granted for indications with no therapeutic alternative where a response rate 
≥ 10% was demonstrated. This research aims to define the circumstances under 
which oncologics can obtain both regulatory approval and public reimbursement 
in Canada on this basis. METHODS: All pan-Canadian Oncology Drug (pCODR) 
final recommendations and Provincial Funding Summaries were analysed up to 
26th November 2014 and the supportive trial package and key rationale were 
extracted. RESULTS: 36 submissions were extracted. 4 were pCODR-appraised on 
the basis of single-arm Phase II trial data. 3/4 were recommended (brentuximab 
vedotin [Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma]) and 
vismodegib) with pCODR deeming randomized controlled trials (RCTs) to be not 
feasible due to very small patient numbers and there being no standard of care. All 
3 were also subject to additional restrictions to the approved label. Nevertheless, 
the incremental cost-effectiveness ratios (ICERs) generated on such data packages 
were regarded as highly uncertain; these recommendations were all conditional 
on cost-effectiveness being improved to an acceptable level. Nevertheless, within 
12 months of all these recommendations, provincial approval was attained in ≥ 5 
provinces including the largest 3 (Ontario, Alberta, and British Columbia). For the 
rejected submission (crizotinib), an RCT was deemed feasible and pCODR would 
not make a recommendation in the absence of comparative survival and quality 
of life benefits. A subsequent resubmission including Phase III data was recom-
mended. CONCLUSIONS: pCODR will recommend oncologics based on single-arm 
Phase II data for indications where RCTs are not deemed feasible but discounting 
promote market access leverage. METHODS: Across the United States, 100 medical 
and hematological oncologists and 25 managed care organization (MCO) pharmacy 
and medical directors completed online quantitative surveys to capture their views 
on BTD. RESULTS: Surveyed payers were unanimous that BTD will influence formu-
lary decisions for oncology drugs; some 40% said BTD would result in more favorable 
tier placement, while 37% expect fewer prescribing controls. However, none of our 
surveyed payers considered themselves yet very familiar with the BTD pathway. In 
contrast, one third of surveyed oncologists declared themselves to be very familiar 
with BTD. Furthermore, almost all oncologists said that BTD will affect their prescrib-
ing; almost 50% agreed that an agent with accelerated approval based on Phase II 
data and BTD will more likely be prescribed than such an agent without BTD. Notably, 
while BTD includes no guarantee of access to other regulatory pathways other than 
fast track designation, surveyed oncologists and payers often associate accelerated 
approval and priority review with BTD. CONCLUSIONS: BTD instills confidence in 
payers and prescribers, such that this accolade looks set to positively influence reim-
bursement conditions, drive uptake, and promote market access for a given agent. 
Moreover, associating BTD with accelerated approval and priority review likely further 
inspires positivity towards BTD agents. However, that payer respondents are at least 
somewhat unfamiliar with the BTD pathway must be considered. Manufacturers 
with BTD agents must formulate their market access strategy early and efficiently, 
ensuring that payers are fully aware of the benefits and advantages that secured 
this classification.
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OBJECTIVES: To capture the trends in opioid prescribing and to determine whether 
rural residency impacts opioid prescribing patterns. METHODS: We used the National 
Ambulatory Medical Care Survey (NAMCS) data available for the years 2006-2010. The 
NAMCS data is a nationally representative annual survey of the provision and utiliza-
tion of outpatient medical care services in the US. Main outcome measure was opioid 
drug prescribed. Survey weighted logistic regression models were fit to determine 
factors influencing opioid prescribing. RESULTS: Opioid prescriptions increased from 
10% in 2006 to 12% in 2010. There was an increasing trend in rural opioid prescribing 
(11% in 2006, 12% in 2007, 14% in 2008, 15% in 2009 and 2010) as compared with urban 
location (10% from 2006-2008, 12% in 2009 and 11% in 2010). Primary care physicians 
and medical professionals were more likely to prescribe opioids (13% in 2006, 12% in 
2007, 16% in 2008, 17% in 2009 and 14% in 2010) as compared with surgeons (6%, 11%, 
10%, 10%, 14% respectively). Multivariate analyses revealed that over the years, younger 
patients (35-49 and 50-64), who did not have a cancer diagnosis, and were insured by 
Medicare or other type of insurance were more likely to get opioid prescription, while 
patients seen by surgeons were less likely to get opioids. CONCLUSIONS: Our study 
poses significant implications for healthcare professionals and policy makers. Our 
study not only demonstrated that rural residents were more likely to be prescribed opi-
oids but it showed an upward trend in rural opioid prescribing which was significantly 
different from urban locations. Increased prescribing of opioids, has led to a growing 
problem of prescription drug abuse especially among rural residents. Further research 
is warranted to study the extent of over prescribing and abuse in rural communities.
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OBJECTIVES: The pan-Canadian Oncology Drug Review (pCODR) was established in 
2010 to appraise oncology drugs in order to help guide provincial reimbursement 
decision-making. pCODR is currently being transferred to Canadian Agency for Drugs 
and Technologies in Health (CADTH) offering the opportunity for reform. This research 
aims to measure the impact of this process on access to oncology drugs in Canada 
and compare this with Quebec, which does not refer to pCODR. METHODS: All pub-
lished pCODR and Institut national d’excellence en santÃ© et en services sociaux 
(INESSS, the Quebec Health Technology Assessment body) reports were identified 
alongside pCODR provincial funding summaries up to 30 September 2014 and the 
dates, decision, and key rationale were extracted. All statistical comparisons were 
made using ANOVA and t-tests. RESULTS: Most (62% [21/34]) pCODR recommen-
dations were conditional on cost-effectiveness being demonstrated (20% recom-
mended, 18% not recommended). Following pCODR recommendations, an average 
of 6.7 months from submission, there is an additional average 8.9 month delay for 
provincial funding decision-making. The time required for provincial decision making 
was no faster for drugs recommended by pCODR versus those conditional on accept-
able cost-effectiveness (9.3 vs. 9.3 months, p= 0.49). INESSS issued recommendations 
for these corresponding oncology drugs an average of only 2.1 months after pCODR, 
6.8 months before the other provinces, a difference which is statistically significant 
(p= 0.0013). CONCLUSIONS: Given that the key issue for most candidate oncologics 
facing reimbursement is cost-effectiveness, pCODR issuing large numbers of rec-
ommendations conditional on cost-effectiveness being demonstrated adds a time-
consuming step that does not speed provincial decision making. INESSS, operating 
independently to pCODR, issue recommendations significantly sooner than other 
provinces. Based on this, we recommend that acceptable pCODR cost-effectiveness 
be a mandatory requirement prior to provincial consideration or that the pCODR 
process be curtailed into just providing a clinical benefit assessment.
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